glp-1 and muscle loss Sarcopenia in the era of receptor agonists: Implications for the internist GLP-1 Muscle Loss Explained |

This mechanism is especially relevant because metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), frequently accompanies obesity and type 2 diabetes

Optimization was performed by comparing the expression levels of fusion proteins and evaluating their agonistic activity towards GLP-1R, antagonistic activity towards GIPR, pharmacokinetic properties, as well as changes in body weight and blood glucose levels

Cirincione B, Edwards J, Mager DE

adults are overweight, with BMIs of 25 to 29, according to data from the U.S

15,19,22,23,31,32,38,39,41,43 TAKE-HOME MESSAGE Lifestyle modification remains the foundation of MASH management, 9 with weight loss of at least 10% associated with fibrosis regression in most patients

Skipping screens before bed (yes, that phone counts!)